ZYVERSA THERAPEUTICS INC (ZVSA)

Company Profile

Zyversa Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Weston, Florida and currently employs 7 full-time employees. The company went IPO on 2021-12-21. ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company. The firm is focused on leveraging advanced technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its development pipeline includes a renal drug candidate, namely VAR 200 (2-hydroxypropyl-beta-cyclodextrin or 2HPβCD), a cholesterol efflux mediator for the treatment of a rare kidney disease, focal segmental glomerulosclerosis. Its VAR 200 has the potential to treat other glomerular diseases, including alport syndrome and diabetic kidney disease. Its lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS). The firm's development pipeline also includes an anti-inflammatory drug candidate, namely IC 100, an inflammasome ASC inhibitor being developed to treat a multitude of inflammatory diseases. Its renal product candidate, VAR 200, mediates the removal of excess intracellular lipids that contribute to kidney damage and lead to end-stage renal disease.

Company Info

ZYVERSA THERAPEUTICS INC

2200 N. Commerce Parkway, Suite 208

Weston FLORIDA

P: 17542311688

Employees: 7

Website: https://www.zyversa.com/